The global pollen allergy market, valued at approximately USD 5850.8 million in 2023, is on a promising growth trajectory, driven by advancements in healthcare technology. With a projected compound annual growth rate (CAGR) of 4.2%, the market is anticipated to expand substantially, reaching an estimated USD 8828.6 million by 2033.
The increase in market value reflects the rising prevalence of pollen allergies and the growing demand for effective treatment solutions. Advances in healthcare technology are playing a pivotal role in driving this growth, enhancing diagnostic tools, and expanding treatment options for individuals affected by pollen allergies.
Secure Your Sample Report and Stay Ahead in the Dynamic Pollen Allergy Market
As pollen allergies become increasingly common due to environmental changes and urbanization, the market is witnessing heightened investments in research and development. Innovative therapies and diagnostic techniques are emerging, aimed at improving patient outcomes and managing allergy symptoms more effectively.
FMI, a leader in allergy treatment and research, emphasizes the significance of these advancements in shaping the future of allergy care. “The growth of the pollen allergy market underscores the critical need for continued innovation in healthcare. Our commitment to advancing treatment solutions aligns with the market’s trajectory and the evolving needs of patients worldwide,” said FMI.
The expanding market is expected to provide numerous opportunities for stakeholders, including pharmaceutical companies, healthcare providers, and research institutions. The focus on technological innovations and patient-centered approaches will be key drivers in shaping the future landscape of the pollen allergy market.
Key Takeaways from the Market Study:
- As of 2023, the pollen allergy industry was valued at USD 5850.8 Million
- From 2023 to 2033, the pollen allergy industry is poised to grow at a 4.2% CAGR
- By 2033, the pollen allergy industry is slated to reach a valuation of USD 8828.6 Million
- Based on therapeutic drug class, Corticosteroids dominated the pollen allergy industry in 2023 with a revenue share of 35.5%.
- China is poised to yield a CAGR of 3.8% with respect pollen allergy in 2033
“Technological advancement in healthcare and increase in the prevalence of allergic rhinitis and rise in the number of patients especially children suffering from pollen allergies expected to radically transform the pollen allergy industry in the coming years,” comments an analyst at FMI.
Competitive Landscape:
Some of the leading manufacturers and players assessed in the global pollen allergy industry are
- bioMerieux SA
- HOB Biotech Group Corp Ltd
- Alcon
- HYCOR Biomedical, Inc
- Immunomic Therapeutics
- Quest Diagnostics Incorporated
- Omega Diagnostics Group PLC
- Siemens Healthcare Private Limited
- Stallergenes Greer
- Lincoln Diagnostics, Inc.
Maximize Your Strategy Get Immediate Access to the Full Report
Recent Development:
- In July 2022 – Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.
- Lincoln Diagnostics offers a painless option for skin allergy testing with the Multi-Test PC (pain control). This test still provides high sensitivity, high specificity, and low variability in results but with virtually no pain.
Key Segments Covered in the Pollen Allergy Industry Survey:
Pollen allergy industry by Product Type:
- Instruments
- Consumables
- Services
Pollen allergy industry by Allergen Type:
- Food
- Inhaled
- Drug
- Other
Pollen allergy industry by Therapeutics Drug class:
- Antihistamines
- Decongestants
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anticholinergics
- Immunomodulators
- Auto injectable Epinephrine
- Immunotherapy
Pollen allergy industry by End-User:
- Diagnostic Laboratories
- Hospitals
Pollen allergy industry by Region:
- North America Pollen allergy industry
- Latin America Pollen allergy industry
- Europe Pollen allergy industry
- South Asia Pollen allergy industry
- East Asia Pollen allergy industry
- Oceania Pollen allergy industry
- MEA Pollen allergy industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
